Rick Hirsch, DO
Family Medicine · Upland, CANPI 1497774954
Payments from drug & device makers
Across 95 payments — averaging $43.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$826
- AbbVie$522
- GSK$355
- Bayer$275
- Novo Nordisk$264
- Johnson & Johnson$219
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,086100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $826 |
| AbbVie(2 entities) | 8 | $522 |
| GSK | 6 | $355 |
| Bayer | 2 | $275 |
| Novo Nordisk | 6 | $264 |
| Johnson & Johnson | 7 | $219 |
| Sanofi Pasteur Inc. | 2 | $194 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $189 |
| Medicure Pharma Inc. | 1 | $148 |
| Sunovion Pharmaceuticals Inc. | 1 | $125 |
| Biohaven Pharmaceuticals, Inc. | 2 | $124 |
| Pfizer | 4 | $92 |
| Boehringer Ingelheim | 5 | $81 |
| Exact Sciences | 4 | $76 |
| Sanofi-aventis U.S. LLC | 2 | $75 |
| Cequr Corporation | 1 | $73 |
| Novartis | 3 | $64 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $60 |
| Amgen | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 3 | $47 |
| Teva Pharmaceuticals USA, Inc. | 1 | $38 |
| Lucid Diagnostics Inc. | 2 | $37 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Tolmar, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $23 |
| Ironwood Pharmaceuticals, Inc | 1 | $23 |
| Lilly USA, LLC | 1 | $20 |
| Edwards Lifesciences | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QULIPTA$250
- AIRSUPRA$245
- NURTEC ODT$232
- UBRELVY$228
- Adempas$150
- ZYPITAMAG (pitavastatin)$148
- LONHALA MAGNAIR$125
- Ozempic$122
- TRELEGY ELLIPTA$111
- AREXVY$109
- TEZSPIRE$108
- INVOKANA$106
How this compares
$4,092 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 86 | $82,043 |
| OzempicSemaglutide | 44 | $48,409 |
| EliquisApixaban | 63 | $46,097 |
| FarxigaDapagliflozin Propanediol | 26 | $31,124 |
| JanuviaSitagliptin Phosphate | 29 | $22,392 |
| XareltoRivaroxaban | 23 | $20,363 |
| MyrbetriqMirabegron | 14 | $18,413 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $17,422 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $17,034 |
| RybelsusSemaglutide | 12 | $14,509 |
| LinzessLinaclotide | 13 | $11,770 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $11,269 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $8,393 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $6,455 |
| BelsomraSuvorexant | 14 | $5,961 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $81 | $82,04386 claims |
| Novo NordiskOzempic, Rybelsus | $264 | $62,91856 claims |
| PfizerEliquis | $92 | $46,09763 claims |
| AstraZenecaFarxiga | $826 | $31,12426 claims |
| Johnson & JohnsonXarelto | $219 | $20,36323 claims |
| Astellas Pharma US IncMyrbetriq | $23 | $18,41314 claims |
| GSKTrelegy Ellipta | $355 | $17,42227 claims |
| AbbVieLinzess, Synthroid | $522 | $13,80839 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in Upland
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.